Drug intelligence / Profile preview

MESOHEAL Body HA

Development stage: Unknown
Lead developer: Koru Pharma
Administration: Subcutaneous

Overview

MESOHEAL Body HA is a hyaluronic acid-based body filler developed by Koru Pharmaceuticals for non-surgical body contouring and aesthetic volume restoration. It consists of a highly purified, viscoelastic gel of cross-linked hyaluronic acid (30% cross-linking) produced via proprietary MCO Tech (Micronized Cross-linked Optimization). The product is designed for subcutaneous injection into areas such as the breasts, buttocks, and lower legs to replenish volume, correct skin irregularities following liposuction, and combat cellulite. As a biocompatible filler, it provides structural support and moisture retention through the humectant properties of hyaluronic acid, with effects typically lasting up to two years from a single treatment session.

Brand names: MESOHEAL Body HAMESOHEAL Shape
Other names: Mesoheal

Beyond the preview

Go deeper on MESOHEAL Body HA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MESOHEAL Body HA.

Explore the full profile